The efficacy of a combined approach using chemotherapy plus a PD-1-targeted antibody has been investigated in a study conducted by Otsuka et al. In particular, the authors evaluated the effects of a combination of cisplatin/pemetrexed with an anti-PD-1 antibody in a mouse model consisting of AB1-HA mesothelioma tumors growing s.c. in syngeneic C57BL/6 mice [23]. The gene discussed is PDCD1; the disease is mesothelioma.